Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

alpha(v)beta(3) Antagonists based on a central thiophene scaffold.

A Peyman1, K Scheunemann, D W Will

  • 1Aventis Pharma Deutschland GmbH, D-65926, Frankfurt, Germany. anusch.peyman@aventis.com

Bioorganic & Medicinal Chemistry Letters
|July 17, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Observation of disorder-free localization using a (2+1)D lattice gauge theory on a quantum processor.

Science (New York, N.Y.)·2026
Same author

Search for Light Pseudoscalar Bosons, Pair-Produced in Higgs Boson Decays in the Four-Electron Final State in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2026
Same author

First Evidence for Mixing-Induced CP Violation in B_{s}^{0}→J/ψϕ(1020) Decays in pp Collisions at sqrt[s]=13  TeV.

Physical review letters·2026
Same author

Observation of Suppressed Charged-Particle Production in Ultrarelativistic Oxygen-Oxygen Collisions.

Physical review letters·2026
Same author

Measurement of D^{0} Meson Photoproduction in Ultraperipheral Heavy Ion Collisions.

Physical review letters·2026
Same author

Observation of tWZ Production at the CMS Experiment.

Physical review letters·2026

Researchers developed new potent alpha(v)beta(3) antagonists using a thiophene scaffold. These compounds, including compound 19, show promise for treating osteoporosis by inhibiting cell adhesion.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Biochemistry

Background:

  • Integrin alpha(v)beta(3) plays a crucial role in various physiological processes, including bone resorption.
  • Development of selective antagonists for alpha(v)beta(3) is a therapeutic target for conditions like osteoporosis.
  • Arg-mimetic compounds are essential for designing effective integrin antagonists.

Purpose of the Study:

  • To design and synthesize novel thiophene-based alpha(v)beta(3) antagonists.
  • To evaluate the potency and selectivity of these antagonists against alpha(v)beta(3) and alpha(IIb)beta(3) integrins.
  • To assess the in vivo efficacy of a lead compound in an osteoporosis model.

Main Methods:

  • Synthesis of a series of thiophene derivatives incorporating an acylguanidine moiety.

Related Experiment Videos

  • In vitro assays to measure inhibition of alpha(v)beta(3) mediated cell adhesion.
  • Evaluation of binding affinity and selectivity against alpha(IIb)beta(3).
  • In vivo testing of compound 19 in the TPTX model of osteoporosis.

    • Main Results:

    • Several novel, potent alpha(v)beta(3) antagonists were identified.
    • Structural modifications, including guanidine type and side chains, influenced potency and selectivity.
    • Compound 19 demonstrated significant activity in the TPTX model, suggesting therapeutic potential for osteoporosis.
    • Exploration of cyclic vs. open guanidines and various side chains provided structure-activity relationship insights.

    Conclusions:

    • The described thiophene-based acylguanidines are effective alpha(v)beta(3) antagonists.
    • Compound 19 shows promise as a therapeutic agent for osteoporosis.
    • Further development of these antagonists could lead to new treatments for bone diseases.